We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen

This study has been terminated.
(As of 12/12/12 study closed to enrollment because study was determined to be ineffective.)
ClinicalTrials.gov Identifier:
First Posted: June 3, 2011
Last Update Posted: June 25, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Roger Williams Medical Center
Rhode Island Hospital
The Miriam Hospital
Information provided by (Responsible Party):
howard safran, Brown University
Results First Submitted: February 20, 2014  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Esophageal
Gastrooesophageal Cancer
Gastric Cancer
Intervention: Drug: jevtana

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Real Drug

patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity

jevtana: Cabazitaxel 25mg/m2, IV every 21 days until progression

Participant Flow:   Overall Study
    Real Drug
STARTED   15 [1] 
Progression/worsening of Dx prior to txt                2 
[1] 15 patients were enrolled to the study but only 13 went on to begin treatment

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Patients with metastatic gastroesophageal cancer that have relapsed after at least one line of chemotherapy

Reporting Groups
Real Drug

patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity

jevtana: Cabazitaxel 25mg/m2, IV every 21 days until progression

Baseline Measures
   Real Drug 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 67  (7.9) 
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   5 
>=65 years   8 
[Units: Participants]
Female   2 
Male   11 
Region of Enrollment 
[Units: Participants]
United States   13 

  Outcome Measures

1.  Primary:   Number of Patients Without Progression at 3 Months   [ Time Frame: every three cycles approx every 63 days ]

2.  Secondary:   To Assess the Toxicity Associated With Cabazitaxel for Patients With Metastatic Gastroesophageal Adenocarcinomas That Have Progressed After at Least One Line of Therapy for Metastatic Disease.   [ Time Frame: at approx 6, 12 and 18 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Howard Safran, MD
Organization: BrUOG
phone: 4018633000
e-mail: Hsafran@lifespan.org

Responsible Party: howard safran, Brown University
ClinicalTrials.gov Identifier: NCT01365130     History of Changes
Other Study ID Numbers: BrUOG 243
First Submitted: May 11, 2011
First Posted: June 3, 2011
Results First Submitted: February 20, 2014
Results First Posted: April 28, 2014
Last Update Posted: June 25, 2014